RMC No. 156-2022 updates the VAT-exempt medicines list under the CREATE Act, covering chronic and life-threatening conditions. Businesses must adjust VAT calculations immediately.

Businesses and healthcare providers must now adjust their VAT calculations immediately for certain medicines prescribed for hypertension, diabetes, high cholesterol, tuberculosis, mental illness, and cancer. The Food and Drug Administration’s latest update, endorsed by Revenue Memorandum Circular No. 156-2022, expands the VAT exemption list under the CREATE Act, impacting pricing, invoicing, and tax reporting processes.

What Changed

RMC No. 156-2022 publishes the FDAโ€™s November 23, 2022 letter updating the official list of VAT-exempt medicines under Republic Act No. 11534 (CREATE Act). The updated list now explicitly includes medicines for chronic and life-threatening conditions, signaling a broader scope of VAT relief for patients and healthcare providers. This ensures that these prescribed drugs are no longer subject to the 12% value-added tax.

Who Is Affected

The ruling primarily affects pharmaceutical companies, hospitals, clinics, and pharmacies selling medicines for hypertension, diabetes, high cholesterol, tuberculosis, mental illnesses, and cancer. Accountants, tax compliance officers, and CFOs managing VAT filings must update systems to reflect the exemption immediately. Patients indirectly benefit from the VAT relief as cost reductions should pass through to consumers.

Key Compliance Requirements and Deadlines

Under RMC No. 156-2022, the VAT exemption takes effect on the date of the FDA’s publication of the updated list. Businesses should:

1. Review their current inventory and identify medicines now covered by the exemption.

2. Update point-of-sale and accounting systems to ensure no VAT is charged on exempt medicines.

3. Adjust VAT reporting and input tax claims accordingly for sales and purchases of newly exempt medicines.

4. Maintain documentation evidencing the FDA-endorsed update as support in case of BIR inquiries.

Penalties for Non-Compliance

Failing to correctly apply VAT exemptions could result in additional tax assessments, penalties, and interest under the National Internal Revenue Code. It is critical for affected businesses to implement the updates immediately to avoid non-compliance and potential disputes with the BIR.

Practical Steps for Businesses

Tax teams should coordinate with procurement and pharmacy units to update pricing and billing systems. CFOs and accountants should adjust monthly VAT declarations to reflect exempt sales. Regular staff training on the updated VAT-exempt list can prevent erroneous VAT application. Documentation of system updates and internal memoranda can serve as evidence of compliance during audits.

For companies seeking comprehensive guidance on implementing these VAT exemptions and ensuring full compliance, Ablola, Saribong & Gueco offers expert support in tax advisory and compliance. Visit MakatiLawFirm.com to schedule a consultation and secure your business against VAT errors under the CREATE Act.


Leave a Comment

Your email address will not be published. Required fields are marked *